Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01883817 · ClinicalTrials.gov registry record · Phase 3
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
A Phase 3 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT01883817 is a Phase 3 study that has completed, run by University of Cincinnati. The registered enrollment target is 30 participants.
The verdict
NCT01883817, a Phase 3 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study hypothesis is that DHA is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with ADHD.
Interventions
- DRUG Placebo
- DRUG DHA Omega-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-09 |
| Est. Completion | 2017-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01883817
The ClinicalTrials.gov registry entry for NCT01883817 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01883817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01883817 about?
NCT01883817 is a clinical study titled "Effect of Omega-3 Fatty Acid on Cortical Function in ADHD". The study hypothesis is that DHA is more effective than placebo in increasing brain activation and reducing symptoms in psychostimulant-free children with ADHD.
What is the current status of trial NCT01883817?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2013-09. Estimated completion is 2017-03-03.
What interventions are being tested in trial NCT01883817?
The interventions under investigation include: Placebo (DRUG), DHA Omega-3 (DRUG).
Who is sponsoring clinical trial NCT01883817?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.